Ultragenyx Pharmaceutical... (RARE)
NASDAQ: RARE
· Real-Time Price · USD
29.68
0.67 (2.31%)
At close: Aug 15, 2025, 3:59 PM
29.87
0.62%
After-hours: Aug 15, 2025, 07:57 PM EDT
Ultragenyx Pharmaceutical Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 610.16M | 590.69M | 560.23M | 522.75M | 481.3M | 442.59M | 434.25M | 410.2M | 402.86M | 383.89M | 363.33M | 343.37M | 334.31M | 331.95M | 351.41M | 359.56M | 359.38M | 334.12M |
Cost of Revenue | 98.2M | 96.72M | 94.44M | 89.59M | 79.56M | 59.33M | 45.21M | 38.48M | 36.12M | 34.48M | 28.32M | 26.51M | 22.05M | 16.92M | 16.01M | 17.98M | 16.15M | 14.82M |
Gross Profit | 511.96M | 493.97M | 465.8M | 433.15M | 401.75M | 383.26M | 389.04M | 371.73M | 366.74M | 349.41M | 335.01M | 316.86M | 312.26M | 315.03M | 335.4M | 341.58M | 343.23M | 319.3M |
Operating Income | -505.09M | -513.57M | -535.97M | -535.74M | -548.85M | -580.45M | -569.21M | -592.79M | -672.76M | -666.39M | -648.92M | -605.86M | -470.62M | -411.8M | -381.74M | -375.25M | -335.74M | -316.02M |
Interest Income | 32.91M | 34.51M | 36.51M | 35.51M | 30.66M | 29.22M | 26.69M | 24.33M | 21.93M | 16.87M | 11.07M | 5.32M | 2.24M | 1.78M | 1.93M | 2.47M | 3.4M | 4.76M |
Pretax Income | -530.39M | -547.13M | -567.59M | -561.07M | -586.86M | -615.22M | -608.46M | -634.86M | -714.68M | -713.44M | -701.73M | -670.88M | -504.88M | -468.98M | -452.98M | -354.48M | -350.2M | -202.5M |
Net Income | -532.93M | -549.58M | -569.18M | -558.99M | -585.12M | -613.35M | -606.64M | -635.28M | -720.74M | -719.07M | -707.42M | -678.05M | -505.94M | -470.2M | -454.02M | -355.58M | -351.43M | -203.68M |
Selling & General & Admin | 337.29M | 331.25M | 321.61M | 315.95M | 310.51M | 311.31M | 309.8M | 305.81M | 300.74M | 287.47M | 278.14M | 264.72M | 248.76M | 234.04M | 219.98M | 211.59M | 199.83M | 188.68M |
Research & Development | 679.76M | 676.29M | 680.16M | 652.95M | 640.09M | 652.39M | 648.45M | 658.7M | 738.75M | 728.33M | 705.79M | 657.99M | 534.11M | 492.79M | 497.15M | 505.24M | 479.14M | 446.64M |
Other Expenses | n/a | -1.83M | -3.43M | -1.39M | -1.39M | -1.55M | 54K | -1.99M | 389K | 1.45M | 1.74M | 1.77M | -618K | 686K | 241K | 1.49M | 2.05M | 1.89M |
Operating Expenses | 1.02B | 1.01B | 1B | 968.9M | 950.6M | 963.71M | 958.25M | 964.51M | 1.04B | 1.02B | 983.93M | 922.72M | 782.88M | 726.83M | 717.13M | 716.83M | 678.97M | 635.32M |
Interest Expense | 59.62M | 61.54M | 63.04M | 64.85M | 66.8M | 66.22M | 66M | 64.55M | 61.39M | 52.07M | 43.02M | 30.95M | 25.12M | 27.59M | 29.42M | 33.82M | 33.72M | 33.63M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 3.53M | 3.53M | 3.53M |
Cost & Expenses | 1.12B | 1.1B | 1.1B | 1.06B | 1.03B | 1.02B | 1B | 1B | 1.08B | 1.05B | 1.01B | 949.23M | 804.93M | 743.75M | 733.14M | 734.81M | 695.12M | 650.14M |
Income Tax Expense | 2.54M | 2.45M | 1.6M | -2.09M | -1.74M | -1.86M | -1.82M | 426K | 6.06M | 5.63M | 5.7M | 7.17M | 1.06M | 1.22M | 1.04M | 1.09M | 1.23M | 1.18M |
Shares Outstanding (Basic) | 98.46M | 96.29M | 95.68M | 95.49M | 86.58M | 84.29M | 81.12M | 71.66M | 70.9M | 70.37M | 70.15M | 70.05M | 69.93M | 69.52M | 68.57M | 67.88M | 67.61M | 67.1M |
Shares Outstanding (Diluted) | 98.46M | 96.29M | 95.68M | 95.49M | 86.58M | 84.29M | 81.12M | 71.66M | 70.9M | 70.37M | 70.15M | 70.05M | 69.93M | 69.52M | 68.57M | 67.88M | 67.61M | 67.1M |
EPS (Basic) | -5.53 | -5.88 | -6.34 | -6.47 | -7.3 | -8.03 | -8.33 | -8.97 | -10.24 | -10.25 | -10.11 | -9.74 | -7.32 | -6.87 | -6.71 | -5.29 | -5.34 | -3.12 |
EPS (Diluted) | -5.53 | -5.88 | -6.34 | -6.47 | -7.3 | -8.03 | -8.33 | -8.97 | -10.24 | -10.25 | -10.11 | -9.74 | -7.32 | -6.87 | -6.71 | -5.29 | -5.34 | -3.12 |
EBITDA | -435.33M | -449.9M | -469M | -461.55M | -486.94M | -518.69M | -515.75M | -546.86M | -632.34M | -642M | -640.49M | -623.14M | -464.43M | -427.43M | -410.32M | -307.83M | -303.77M | -156.1M |
EBIT | -470.77M | -485.59M | -504.55M | -496.23M | -520.06M | -549M | -542.46M | -570.31M | -653.29M | -661.37M | -658.71M | -639.93M | -479.75M | -441.39M | -423.56M | -320.67M | -316.49M | -168.88M |
Depreciation & Amortization | 35.45M | 35.69M | 35.54M | 34.68M | 33.12M | 30.32M | 26.71M | 23.45M | 20.95M | 19.37M | 18.22M | 16.8M | 15.32M | 13.96M | 13.24M | 12.84M | 12.71M | 12.78M |